Delveinsight Business Research LLP
DelveInsight’s “Inclusion Body Myositis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Inclusion Body Myositis, historical and forecasted epidemiology as well as the Inclusion Body Myositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Inclusion body myositis (IBM) is a slowly progressive skeletal muscle disease with unique clinical and pathological features (including finger flexor and quadriceps weakness and the presence of infiltrating cytotoxic T cells in muscle). IBM is classified along with polymyositis, dermatomyositis, and autoimmune necrotizing myopathy as one of the idiopathic inflammatory myopathies (a group of disorders characterized by inflammation of the skeletal muscle).

IBM has unique physical examination features(such as finger flexor and knee extensor weakness) that distinguish it from most other muscle diseases. Inclusion body myositis (IBM) progresses slowly and is commonly misdiagnosed initially as arthritis or polymyositis; IBM is associated with cardiovascular complications and other autoimmune diseases and has a high economic cost.

Novel treatment options, better disease understanding along with increasing awareness regarding, are responsible for the growth of the IBM therapeutic market.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/inclusion-body-myositis-market

Inclusion Body Myositis Market

The Inclusion Body Myositis market report also covers emerging drugs, current treatment practices, Inclusion Body Myositis market share of the individual therapies, current and forecasted Inclusion Body Myositis Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Inclusion Body Myositis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Inclusion Body Myositis Market Key Facts

  • According to a study titled “Inclusion Body Myositis” conducted by Mazen M. Dimachkie et al.,(2014) in an Olmsted County population study the estimated incidence of IBM, adjusted for sex and age to the 2000 US Census population, was 7.9 cases per million inhabitants with a prevalence of 70 cases per million inhabitants. 

  • A study titled “Epidemiology of sporadic inclusion body myositis”, 2016 specified that recent work estimated the population prevalence of sporadic IBM in Northern Europe to 3.3/100 000, which is higher than in previous studies.

  • A Study titled “.Increase in the number of sporadic inclusion body myositis (sIBM) in Japan”, 2012, quoted that data from Japan indicated that the prevalence was less than 10 per million in 2003, but rising towards 2012.

Key Benefits of Inclusion Body Myositis Market Report

  • Inclusion Body Myositis market report provides an in-depth analysis of Inclusion Body Myositis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Inclusion Body Myositis market report will help in developing business strategies by understanding the Inclusion Body Myositis Market trends & developments, key players, and future market competition that will shape and drive the Inclusion Body Myositis market in the upcoming years.

  • The Inclusion Body Myositis market report covers Inclusion Body Myositis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Inclusion Body Myositis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Inclusion Body Myositis Market

Inclusion Body Myositis market size is expected to increase during the forecast period owing to the high prevalence of the disorder and growing geriatric population in the 7MM. The expected launch of therapies will also fuel the market growth.

The Inclusion Body Myositis market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Inclusion Body Myositis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Inclusion Body Myositis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Inclusion Body Myositis Epidemiology

The Inclusion Body Myositis epidemiology section covers insights about the historical and current Inclusion Body Myositis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Inclusion Body Myositis Epidemiology Segmentation –

  • Age-Specific Prevalent Cases 

  • Prevalent Cases 

  • Symptom-Specific Prevalent Cases

  • Symptom-Specific Prevalent Cases 

  • Diagnosed and Treatable Cases

Inclusion Body Myositis Drugs Uptake and Key Market Players

The Inclusion Body Myositis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inclusion Body Myositis market or expected to get launched in the market during the study period. The analysis covers Inclusion Body Myositis market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The pipeline for IBM is not robust despite the tremendous progress that has been made in the clinical and pathogenic understanding of IBM over the past decade. Increasing prevalence and rising demand for advanced therapeutics for specific and effective treatment of IBM are expected to fuel the market growth during the forecast period.

Inclusion Body Myositis Companies:
Orphazyme
Alzehon
Kv1.3 Therapeutics
And many more.

Inclusion Body Myositis Therapies covered in the report include:
Arimoclomol
ALZ-507
Dalazatide
And many others.

Table of Content

1. Key Insights

2. Executive Summary 

3. Inclusion Body Myositis Competitive Intelligence Analysis

4. Inclusion Body Myositis Market Overview at a Glance

5. Inclusion Body Myositis Disease Background and Overview

6. Inclusion Body Myositis Patient Journey

7. Inclusion Body Myositis Epidemiology and Patient Population

8. Inclusion Body Myositis Treatment Algorithm, Current Treatment, and Medical Practices

9. Inclusion Body Myositis Unmet Needs

10. Key Endpoints of Inclusion Body Myositis Treatment

11. Inclusion Body Myositis Marketed Products

12. Inclusion Body Myositis Emerging Therapies

13. Inclusion Body Myositis Seven Major Market Analysis

14. Attribute Analysis

15. Inclusion Body Myositis Market Outlook (7 major markets)

16. Inclusion Body Myositis Access and Reimbursement Overview

17. KOL Views on the Inclusion Body Myositis Market.

18. Inclusion Body Myositis Market Drivers

19. Inclusion Body Myositis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/inclusion-body-myositis-market

Latest Reports By DelveInsight –
US Healthcare Market Outlook
DelveInsight’s, “US Healthcare Outlook Report, 2020,” report provides comprehensive insights about healthcare scenarios, regulatory policies, and reimbursement landscape in the US. The report also identifies key trends in the healthcare market and provides insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of the US.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Leave a Reply

Your email address will not be published. Required fields are marked *